Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples. by Nalumansi, Aminah et al.
International Journal of Infectious Diseases 104 (2021) 282–286Field evaluation of the performance of a SARS-CoV-2 antigen rapid
diagnostic test in Uganda using nasopharyngeal samples
Aminah Nalumansia,1, Tom Lutaloa,1, John Kayiwaa,1, Christine Wateraa,
Stephen Balinandia, Jocelyn Kiconcoa, Joweria Nakaseegua, Denis Olaraa,
Emmanuel Odwiloa, Jennifer Serwangaa,b, Bernard Kikairea, Deogratius Ssemwangaa,b,
Susan Nabaddac, Isaac Ssewanyanac, Diana Atwined, Henry Mwebesad,
Henry Kyobe Bosae, Christopher Nserekof, Matthew Cottenb, Robert Downinga,
Julius Lutwamaa, Pontiano Kaleebua,b,*
aUganda Virus Research Institute, P.O. Box 49, Plot 51–59, Nakiwogo Road, Entebbe, Uganda
bMedical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine, Uganda Research Unit, P.O. Box 49, Plot 51–
59, Nakiwogo Road, Entebbe, Uganda
cCentral Public Health Laboratories, P.O. Box 7272, Plot 1062–106, Old Butabika Road, Kampala, Uganda
dMinistry of Health, P.O. Box 7272, Plot 6, Lourdel Road, Kampala, Uganda
e Public Health Emergency Operations Centre, P.O. Box 7272, Lourdel Towers, Plot 1 Lourdel Road, Kampala, Uganda
f Entebbe Regional Referral Hospital, P.O. Box 29, Kampala Road, Entebbe, Uganda
A R T I C L E I N F O
Article history:
Received 15 July 2020
Received in revised form 22 October 2020








A B S T R A C T
Objectives: There is a high demand for SARS-CoV-2 testing to identify COVID-19 cases. Real-time
quantitative PCR (qRT-PCR) is the recommended diagnostic test but a number of constraints prevent its
widespread implementation, including cost. The aim of this study was to evaluate a low cost and easy to
use rapid antigen test for diagnosing COVID-19 at the point of care.
Methods: Nasopharyngeal swabs from suspected COVID-19 cases and low-risk volunteers were tested
with the STANDARD Q COVID-19 Ag Test and the results were compared with the qRT-PCR results.
Results: In total, 262 samples were collected, including 90 qRT-PCR positives. The majority of samples
were from males (89%) with a mean age of 34 years and only 13 (14%) of the positives were mildly
symptomatic. The sensitivity and specificity of the antigen test were 70.0% (95% confidence interval (CI):
60–79) and 92% (95% CI: 87–96), respectively, and the diagnostic accuracy was 84% (95% CI: 79–88). The
antigen test was more likely to be positive for samples with qRT-PCR Ct values 29, with a sensitivity of
92%.
Conclusions: The STANDARD Q COVID-19 Ag Test performed less than optimally in this evaluation.
However, the test may still have an important role to play early in infection when timely access to
molecular testing is not available but the results should be confirmed by qRT-PCR.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
In the absence of treatment for coronavirus disease 2019
(COVID-19) or a vaccine for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), public health experts recommend
speedy and accurate testing, followed by case identification,
isolation, and contact tracing as the best approaches to contain this
new disease. COVID-19 was declared a pandemic by the World
Health Organization (WHO) on March 11, 2020. Identifying people
infected with the virus is complicated by the high overlap between
the clinical symptoms of COVID-19 and those of other respiratory
infections, and by the fact that many infected individuals are
asymptomatic (Yang et al., 2020; Lavezzo et al., 2020). Therefore,
accurate diagnostic testing for case identification, quarantine, and
contact tracing is essential for managing this pandemic.
The global demand for testing has put a substantial strain on
governments and institutions. The gold standard diagnostic test
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reverse transcription PCR (qRT-PCR), where the viral RNA is

























































A. Nalumansi, T. Lutalo, J. Kayiwa et al. International Journal of Infectious Diseases 104 (2021) 282–286In Uganda, SARS-CoV-2 qRT-PCR testing started at the Uganda
irus Research Institute (UVRI) in early February 2020 using the
erlin protocol (Corman et al., 2020). All testing in Uganda was
erformed at the UVRI for the initial two months before
ecentralization. The first confirmed case was detected on March
1, 2020. By mid-July, Uganda had conducted 230,680 tests, which
as the highest number in East Africa, and 1040 COVID-19
nfections were reported. The majority of these infections were
mported by truck drivers at the border crossings with neighboring
ountries. These point-of-entry cases require rapid result turn-
round times to ensure early interventions and avoid the
ransmission of infection to local communities as well as limiting
he disruption of commercial transportation.
qRT-PCR testing is usually performed in designated, specialized
aboratories that require well-trained staff and the test typically
akes 4–6 h to complete. The time required to ship clinical samples
o the laboratory and then return the results to health facilities
eads to an overall turnaround time of 24–48 h. Thus, prolonged
eriods of isolation are required for suspected cases and delayed
ontact tracing could further increase the spread of the infection
ithin the country. The cost of qRT-PCR is also prohibitive and
urther complicated by global procurement challenges, where
ost reagents currently take 1–2 months for delivery. To overcome
hese constraints, simple, low cost, and easy-to-use rapid antigen
iagnostic tests are urgently required at the point of care.
Several antibody and antigen rapid diagnostic tests (RDTs) that
an be used by staff with minimal training are now available on the
arket and they are attractive options for the decentralization of
esting. Antibody tests are used for surveillance and epidemiologi-
al research, and to identify recent or past infections, whereas
ntigen RDTs could be an alternative to qRT-PCR for detecting acute
nfection. Moreover, in recent guidance, the WHO proposed
ettings where antigen RDTs can be used in patient management
WHO, 2020b). However, there have been few field evaluations of
hese antigen RDTs (Scohy et al., 2020; Porte et al., 2020; Lambert-
iclot et al., 2020; Mertens et al., 2020; Diao et al., 2020; Mak et al.,
020; ICMR, 2020) and those evaluated yielded disappointing
esults in terms of their performance.
In Uganda, all new molecular testing kits and immunoassays
hat are introduced into the market must undergo in-country
aboratory verification at UVRI, which is a designated WHO and
frica CDC SARS-CoV-2 reference laboratory, before being recom-
ended to the Ministry of Health for use in the country. The WHO
lso advises that tests should be verified in appropriate popula-
ions and settings before they are recommended (WHO Bulletin,
017; ECDC, 2020).
No immuno-assays have been recommended for use in Uganda.
n the present study, we evaluated the performance characteristics
f the STANDARD Q COVID-19 Ag Test (SD Biosensor, Gyeonggi-do,
6690, Korea) compared with qRT-PCR (Berlin protocol) using
asopharyngeal swabs. Our results may be useful for other
eference laboratories in order to meet the demand for SARS-
oV-2 diagnosis.
aterials and methods
tudy design and participants
In this study, we conducted a cross-sectional, prospective, un-
Sample collection
Sample collection was coordinated by a team of laboratory staff
from UVRI. Two nasal swabs were collected by laboratory
personnel at the COVID-19 treatment facilities while taking all
necessary biosafety precautions, where a swab was collected from
each nostril. One swab was tested immediately at the facility using
the STANDARD Q COVID-19 Ag Test, and the result was interpreted
according to the manufacturer’s guidelines and recorded in an
Excel worksheet. The second swab was preserved in specimen
transport medium and transported at 4 C to the UVRI laboratory
for extraction and qRT-PCR testing (Corman et al., 2020).
All testing followed the procedures described in the Uganda
National Council for Science and Technology (UNCST) approved
protocol “Uganda Virus Research Institute; Performance Evalua-
tion for CVID-19 Diagnostic Tests” (http://www.uvri.go.ug/proj-
ects/covid-19).
Antigen test
The STANDARD Q COVID-19 Ag Test is a rapid chromatographic
immunoassay for the qualitative detection of SARS-CoV-2 specific
antigens present in the human nasopharynx. According to the
manufacturer's “Information for Use” (IFU), the results are
available within 30 min. All necessary reagents to perform the
assay are provided by the manufacturer and no assay-specific,
specialized equipment is needed. According to the IFU, the assay
kits are stable when stored at 2–30 C.
qRT-PCR
RNA extraction
RNA was extracted from clinical samples using a viral RNA mini
kit (QIAGEN, Hilden, Germany).
qRT-PCR (Berlin Protocol)
Oligonucleotides were synthesized and provided by Metabion
(http://www.metabion.com). Thermal cycling was performed at
55 C for 10 min for reverse transcription, followed by 95 C for
3 min and then 45 cycles at 95 C for 15 s and at 58 C for 30 s. qRT-
PCR was performed using an Applied Biosystems PCR platform.
Statistical methods
Table A1
Participating sites and samples collected.
Facility Number of participants Proportion (%)
Arua RRH 8 3.1
Entebbe RRH 54 20.6
Fort Portal RRH 1 0.4
Gulu RRH 11 4.2
Jinja RRH 2 0.8
Kasenyi Military Barracks 91 34.7
Lira RRH 8 3.1
Masaka RRH 20 7.6
Mbale RRH 4 1.5
Mulago NRH 30 11.5
UVRI Clinic 33 12.6
Total 262 100linded verification of the performance of the STANDARD Q
OVID-19 Ag Test. Participants were recruited at the regional
eferral hospitals (RRHs) in Arua, Entebbe, Fort Portal, Gulu, Jinja,
ira, Masaka, Mbale, and Mulago National Referral Hospital. The
on-case controls were volunteers at Kasenyi Military Barracks
nd the UVRI clinic (Table A1).28Sensitivity
The sensitivity was calculated as the number of specimens
identified as positive by the STANDARD Q COVID-19 Ag test divided
by the number of specimens identified as positive by the qRT-PCR
reference assay, and expressed as a percentage.3
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The specificity was calculated as the number of specimens
identified as negative by the STANDARD Q COVID-19 Ag test
divided by the number of specimens identified as negative by the
qRT-PCR reference assay, and expressed as a percentage.
Accuracy
The accuracy was calculated as the proportion of STANDARD Q
COVID-19 Ag Test results that agreed with the qRT-PCR results
(positive and negative), and expressed as a percentage.
The sensitivity, specificity, and accuracy calculations were
performed using the proportion command in STATA1 15, which
also generated the 95% confidence intervals (CIs).
Comparison of cycle threshold (Ct) values with antigen assay results
We determined the relationship between the viral load
measured as the qRT-PCR Ct value and antigen detection. Ct
values were categorized as strongly positive (Ct  29) indicating
abundant target nucleic acid in the sample, moderately positive
(Ct = 30–37), and weakly positive (Ct = 38–39), and compared with
the STANDARD Q COVID-19 Ag Test results.
Ethical considerations
The evaluation protocol was reviewed and approved by UVRI’s
Research Ethics Committee and the UNCST. Specimens were
unlinked to personal identifiers and results could not be traced to
individual patients. Consent to participate and to store samples for
future use was also sought.
Results
Demographic characteristics
In total, 90 COVID-19 cases and 172 controls (total 262) were
included in this evaluation. The majority were males (89%) and the
overall mean age was 34 years (95% CI: 32–35 years; Table 1).
Performance characteristics
Test results distribution
The distribution of the STANDARD Q COVID-19 Ag Test results
versus the qRT-PCR results is presented in Table 2. Overall, 76
(29.0%) specimens were antigen-positive and 186 (71%) specimens
were antigen-negative.
Sensitivity and specificity
The sensitivity of the STANDARD Q COVID-19 Ag Test was 70%
(95% CI: 60–79%) and the specificity was 92% (95% CI: 87–96%).
Accuracy, false positive rate, and false negative rate
The accuracy of the STANDARD Q COVID-19 Ag Test was 84%
(95% CI: 79–88%). The false positive rate was 8% (95% CI: 4–13%)
and the false negative rate was 30% (95% CI: 21–40%). No factors
were associated with false positives, and they found in all age
categories and RRHs.
Associations between Ct values and STANDARD Q COVID-19 Ag Test
results
The associations between the Ct values and STANDARD Q
COVID-19 Ag test results are shown in Table 3. As expected, the
STANDARD Q COVID-19 Ag Test result was more likely to be
positive when a specimen contained abundant target nucleic acid,
where 92% of the specimens with a strong positive qRT-PCR result
were positive according to the STANDARD Q COVID-19 Ag test. Only
50% of the specimens categorized as moderately and weakly
positive samples by qRT–PCR were positive with the antigen test
(p < 0.01).
Discussion
The WHO recently issued interim guidance regarding the use of
antigen RDTs for patient management. As a minimum require-
ment, Ag-RDTs should correctly identify significantly more cases
than they miss (sensitivity  80%) and exhibit very high specificity
(97–100%) (WHO, 2020b).
If any of the antigen detection tests that are under development
exhibit adequate performance, they could potentially be used as
triage tests to rapidly identify patients who are very likely to have
COVID-19, thereby reducing or eliminating the need for expensive
nucleic acid amplification testing (ICMR, 2020).
In this evaluation of the STANDARD Q COVID-19 Ag Test, a
commercial antigen RDT, we found that the sensitivity and
specificity of the test were 70% and 92% respectively. Overall,
after combining both the positive and negative samples, the
accuracy of the test was determined as 84%.
In the present evaluation, the sensitivity was lower than that
reported by the manufacturer (70% compared with 84.38%) and the
difference was statistically significant (p < 0.001). Similarly, the
specificity in this evaluation was significantly lower than that
reported by the manufacturer (92% compared with 100%). These
discrepancies may have been due partly to the limitations of this
study, as discussed in the following.
With a sensitivity of 70%, the STANDARD Q COVID-19 Ag Test
would not detect 30 out of 100 qRT-PCR positive samples. Similarly,
with a specificity of 92%, the STANDARD Q COVID-19 Ag Test would
find that eight out of 100 qRT-PCR negative samples were positive.
Timely testing is crucial in order to contain the pandemic.
Currently, most qRT-PCR-based testing is conducted in designated,
specialized laboratories, which are far from many sample
collection sites or patients and their contacts, thereby leading to
long turnaround times for results reporting, as well as delaying
isolation and contact tracing to possibly risk increasing the further
Table 1
Demographic characteristics of study participants.
Table 2
STANDARD Q COVID-19 Ag test results compared with the qRT-PCR reference
assays.
STANDARD Q COVID-19 Ag test result qRT-PCR test result Total
Positive Negative
Positive 63 (83) 13 (17) 76 (29)
Negative 27 (15) 159 (86) 186 (71)
Total 90 (34) 172 (66) 262 (100)Participants Mean Age (95% CI) Gender Total
Males (%) Females (%)
Cases 37 (35–39) 85 (94) 5 (6) 90 (34)
Not Cases 32 (31–34) 149 (87) 23 (13) 172 (66)
Total 34 (32–35) 234 (89) 28 (11) 262
284spread of the virus within the country.
Decentralized testing using mobile PCR laboratories and point-
of-care GeneXpert platforms has been introduced in Uganda to
shorten the turnaround time for results. However, challenges still
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f entry would be a significant improvement compared with
urrent practice. The results obtained in this study showed that the
B Biosensor antigen RDT exhibited less than optimal performance
ecause the ideal test would have a sensitivity >95% and specificity
f 100%. The STANDARD Q COVID-19 Ag Test (Gyeonggi-do, 16690,
orea) performed better (sensitivity = 84.38%, specificity = 100%)
uring its validation by the manufacturer in Malaysia (STANDARD
 COVID-19 Ag Test IFU) and in a two-site evaluation in India (ICMR
020) (sensitivity = 50.6% and 84.0%, specificity = 99.3% and 100%).
The few previously published field evaluations of SARS-CoV-2
ntigen RDTs reported mixed results. In three separate studies
Scohy et al., 2020; Lambert-Niclot et al., 2020; Mertens et al.,
020), the COVID-19 Ag Respi-Strip (Coris Bioconcept, Gembloux,
elgium) was found to exhibit good specificity (99.5–100%) but low
ensitivity (30.2–57.6%) compared with qRT-PCR. Another RDT
alled the BIOCREDIT COVID-19 Ag test (RapiGEN Inc., Gyeonggi-
o, 14119, Korea) (Mak et al., 2020) also exhibited low sensitivity
11.1–45.7% with specimens from the nasopharynx, throat, saliva,
nd sputum) and the authors concluded that this test can only be
sed as an adjunct to the qRT-PCR test because of the potential for
alse-negative results.
However, two other studies reported the good performance of
nother antigen test called the Fluorescence Immunochromato-
raphic SARS-CoV-2 Antigen Test (Bioeasy Biotechnology Co.,
henzhen, China). In a study of 127 participants in Chile (Porte
t al., 2020), the overall sensitivity and specificity were 93.9% and
00%, respectively, and the accuracy was 96.1%. In a second study of
39 participants in China (Diao et al., 2020), the overall sensitivity
nd specificity were 67.8% and 100%, respectively. Similar to our
tudy, the sensitivity in both studies was significantly higher in
amples with high viral loads.
Despite its less than optimal performance, the STANDARD Q
OVID-19 Ag test could still play a role in triage (but with
ubsequent selective testing by qRT-PCR) in situations where the
apid isolation of cases is required, e.g., for symptomatic cases or
high-risk” truck drivers at border crossings. In these situations, all
ndividuals identified as COVID-19 positive would require individ-
alized isolation until the qRT-PCR results are available and to
void contact with true positives because a few antigen false-
ositives are actually not infected. This approach can reduce the
ime in isolation for those who are infected and simplify the
ogistics of contact tracing, although the antigen test incurs an
dditional cost.
India has taken a different approach (ICMR, 2020). Following
heir evaluation of the STANDARD Q COVID-19 Ag Test, the Indian
ouncil of Medical Research recommended that for high-risk
roups in containment zones or hotspots and healthcare settings,
suspected individuals who test negative for COVID-19 by rapid
which may have biased their interpretation of the antigen test
result, especially where the RDT bands were weak.
The staff who collected swab samples were different at each
health facility and they had minimal training, which may have
introduced variability into the content or yield of swab material.
Moreover, two swabs were taken from each subject, with one from
each nostril. One was tested immediately with the antigen RDT and
the other was placed in transport medium for subsequent qRT-PCR
testing at UVRI. Thus, the two swabs could be effectively regarded
as two different samples.
The date of exposure was not known for any of the participants
and only 13 of the cases had a date of symptom onset because the
majority of the participants were asymptomatic (86%). Day zero
was taken as the date when the first swab was taken. The analysis
would have benefitted from details of the date of exposure because
the viral load increases over the first 1–2 weeks (Wolfel et al., 2020;
Zou et al., 2020) and it appears to be correlated with the
performance of the antigen test. We observed better sensitivity for
the samples with low Ct values, which were assumed to have
higher viral loads.
Due to logistical constraints, some swab specimens were
transported to UVRI in normal saline rather than viral transport
medium. The WHO recommends the use of normal saline in the
absence of the viral transport medium, but its effect on the
sensitivity of qRT-PCR is not well documented.
The qRT-PCR resultwastaken asthe gold standard. However, both
the qRT-PCR and antigen RDT will miss some infections, particularly
those mentioned above due to limitations in the collection and
transport of swabs. A more significant source of error in this
evaluationwas probably the determination of the qRT-PCR Ct cut-off
value for a positive sample. Thus, the results for specimens with a Ct
value near the cut-off should probably be regardedasprovisionaland
ideally repeated with a fresh sample until the Ct cut-off value for a
positive result can be defined more precisely. In the future, it will be
important to develop standard operating procedures that address
the limitationsmentionedaboveinthepre-analytical,analytical,and
post-analytical phases of testing.
Conclusion
The STANDARD Q COVID-19 Ag Test obtained less than optimal
performance in this evaluation. However, the test may still have an
important role to play early in infection when timely access to
molecular testing is not available, but the results should be
confirmed by qRT-PCR.
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